Omeros (OMER) Other Non-Current Liabilities (2021 - 2026)
Omeros recorded quarterly Other Non-Current Liabilities of $84.0 million in Q1 2026, up 1373.61% quarter-over-quarter from $5.7 million in Q4 2025, and up 1766.81% year-over-year from $4.5 million in Q1 2025.
Omeros' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $84.0 million for Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 1766.81% year-over-year to $84.0 million; the TTM figure through Mar 2026 stood at $84.0 million (up 1766.81% YoY), while the FY2025 annual figure was $5.7 million, up 26.68% from the prior year.
- Other Non-Current Liabilities came in at $84.0 million for Q1 2026 at Omeros, up from $5.7 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $178.1 million in Q2 2025 to a low of $444000.0 in Q4 2022.
- A 5-year average of $27.7 million and a median of $2.1 million in 2023 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities tumbled 60.18% in 2022 and jumped 8428.83% in 2025, its largest moves.
- Omeros' Other Non-Current Liabilities stood at $444000.0 in 2022, then jumped by 370.27% to $2.1 million in 2023, then jumped by 115.57% to $4.5 million in 2024, then advanced by 26.68% to $5.7 million in 2025, then jumped by 1373.61% to $84.0 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $84.0 million, $5.7 million, and $152.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Omeros | 772.03 Mn | 636.71 Mn | 9.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 84.03 Mn |
| Dec 31, 2025 | 5.70 Mn |
| Sep 30, 2025 | 152.53 Mn |
| Jun 30, 2025 | 178.08 Mn |
| Mar 31, 2025 | 4.50 Mn |
| Dec 31, 2024 | 4.50 Mn |
| Sep 30, 2024 | 3.09 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.09 Mn |
| Dec 31, 2023 | 2.09 Mn |
| Jun 30, 2023 | 496,000.00 |
| Mar 31, 2023 | 452,000.00 |
| Dec 31, 2022 | 444,000.00 |
| Sep 30, 2022 | 999,000.00 |
| Jun 30, 2022 | 961,000.00 |
| Mar 31, 2022 | 922,000.00 |
| Dec 31, 2021 | 1.12 Mn |